Half Year Report and Appendix 4D 31 December 2024
Released
Released
Announcement PDF
RAD
RADIOPHARM THERANOSTICS
Interim Report:
Half Year Ended
31 December 2024
Radiopharm Theranostics Limited
Appendix 4D
Half-year report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Radiopharm Theranostics Limited
57 647 877 889
For the half-year ended 31 December 2024
For the half-year ended 31 December 2023
2. Results for announcement to the market
$
Loss from ordinary activities after tax attributable to the owners of
Radiopharm Theranostics Limited
down
20.90% to
(18,725,453)
Loss for the half-year attributable to the owners of Radiopharm
Theranostics Limited
down
20.90% to
(18,725,453)
3. Net tangible assets
31 December 31 December
2024
2023
Cents
Cents
Net tangible assets per ordinary security
0.18
(8.71)
4. Explanation of results
An explanation of the key financial elements contributing to the revenue and result above can be found in the review of
operations included within the directors' report.
5. Distributions
No dividends have been paid or declared by the group for the current financial period. No dividends were paid for the previous
financial period.
6. Changes in controlled entities
There have been no changes in controlled entities during the half-year ended 31 December 2024.
7. Other information required by Listing Rule 4.2A
a. Details of individual and total dividends or distributions and dividend or distribution payments:
b. Details of any dividend or distribution reinvestment plans:
c. Details of associates and joint venture entities:
d. Other information
8. Interim review
The financial statement have been reviewed by the group's independent auditor who has issued an unmodified
opinion.
N/A
N/A
N/A
N/A
Review of Operations & Activities
Half-year ended: 31 December 2024
Radiopharm Theranostics Limited is developing a world-class platform of radiopharmaceutical and
nuclear medicine products for both diagnostic and therapeutic uses.
Financial Review
The group reported a loss for the half-year ended 31 December 2024 of $19,643,011 (31 December
2023: $24,758,296). The decreased loss relates to the groups efforts in reducing their expenditure
in the current period. Additionally, there was a minor gain from the movement in fair value
movements in contingent consideration of $28,060 whereas at 31 December 2023 there was a
significant loss of $5,757,296.
The group’s net assets increased to $52,003,713 (30 June 2024: $27,353,286). The substantial
increase in the group's net assets is, primarily due to the completion of the second tranche of the
June 2024 placement which was approved at the EGM in August 2024. As at 31 December 2024,
the group had cash reserves of $36,436,938 (30 June 2024: $18,575,040).
Clinical and Research Developments
RAD204 – PD-L1 Nanobody Trial Expansion
During the period, Radiopharm achieved key milestones in its ongoing Phase 1 clinical trial of
RAD204, a PD-L1-targeting radiotherapeutic. Initially designed for non-small cell lung cancer
(NSCLC), the trial received approval to expand into five additional cancer indications, including small
cell lung cancer (SCLC), triple-negative breast cancer (TNBC), melanoma, head and neck squamous
cell carcinoma (HNSCC), and endometrial cancer. The expansion allows Radiopharm to explore
RAD204's potential efficacy across a broader spectrum of tumors expressing PD-L1, reinforcing its
strategy of developing tumor-agnostic radiotherapeutics.
The Phase 1 study is progressing across multiple Australian sites, supported by GenesisCare CRO,
with patient recruitment accelerating to meet study targets. Early data has indicated strong tumortargeting capability, favorable biodistribution, and encouraging safety profiles, which are essential
for advancing the clinical development pathway. Additionally, Radiopharm has been leveraging
insights from the initial NSCLC cohort to refine dosing strategies and optimize therapeutic outcomes
across the expanded indications.
First Interim data expected in mid 2025 and full results in Q4 2025/Q1 2026.
RAD101 – Phase 2b Imaging Trial for Brain Metastases
The Company secured U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)
approval for a Phase 2b trial of RAD101 (F18-Pivalate) targeting brain metastases. This follows
positive Phase 2a data from a 22-patient study at Imperial College London, demonstrating
significant tumor uptake and strong imaging contrast.
The Phase 2b study is enrolling 30 patients across multiple sites in the United States and will
evaluate RAD101’s imaging performance in detecting brain metastases with high sensitivity and
1
specificity. The trial will assess both lesion detectability and uptake consistency, supporting its
potential as a new standard for brain metastases imaging. Radiopharm has partnered with BAMF
Health for manufacturing and initial trial execution, leveraging their molecular imaging expertise to
optimize patient recruitment and data collection.
The trial is designed to provide the necessary data to progress into a registrational Phase 3 study,
which would be a critical step toward regulatory approval and commercialization of RAD101 for
clinical use.
RAD202 – HER2-Positive Cancer Therapeutic Trial
In December 2024, Radiopharm obtained ethics approval to initiate a Phase 1 trial of 177Lu-RAD202
for HER2-positive cancers, including breast and gastric cancers. This open-label study, conducted
across multiple Australian sites, aims to assess the safety, tolerability, and initial efficacy of RAD202
in patients with advanced HER2-positive tumors.
Preclinical and diagnostic studies have confirmed RAD202’s tumor uptake and therapeutic
potential, with preclinical models demonstrating significant tumor growth inhibition and prolonged
survival when labeled with 177Lu. The compound is designed to target HER2-overexpressing tumors
with high specificity, minimizing off-target toxicity and enhancing therapeutic efficacy.
The Company presented positive findings at the 2024 European Association of Nuclear Medicine
(EANM) Annual Meeting, highlighting RAD202’s strong tumor-to-background contrast and
promising survival benefits in preclinical models. Radiopharm plans to leverage these results to
accelerate clinical development and explore potential combination strategies with existing HER2targeting therapies.
First Interim data expected in H2 2025.
RAD 301 – Strong Potential for Imaging in Pancreatic Cancer
During November it was announced that a clinical study featuring 68Ga-Trivehexin (68Ga-RAD 301)
had been published in Frontiers in Nuclear Medicine. The paper, entitled “αvβ6-integrin targeted
PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin”1, described the clinical results
of a retrospective study of the biokinetics of 68Ga-RAD 301 in pancreatic cancer patients.
The 44-patient study is reported as the largest cohort of individuals imaged with RAD 301 with any
tracer. The primary tumor, as well as metastases in the liver, lymph nodes, peritoneum, lung, bone,
spleen, pleural cavity, and soft tissues, were visualized with a high tumor-to-background ratio. With
no adverse events recorded, the findings showed that RAD 301 is a suitable and safe diagnostic
agent for imaging αvβ6-integrin expression in pancreatic cancer.
The Phase I IND-approved imaging study in patient with Pancreatic cancer is ongoing in New York,
with full results expected by June 2025.
RAD 301 is a peptide that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic
growth, the expression of which correlates with decreased survival in several carcinomas,
particularly pancreatic.
2
RAD402 – KLK3-Targeting Radiotherapeutic
Preclinical studies for RAD402, a KLK3-targeting radiotherapeutic utilizing Terbium-161 (Tb-161),
were successfully completed during the period. The data demonstrated favorable safety and
biodistribution profiles, with preclinical models indicating significant tumor regression and minimal
off-target toxicity. These results highlight the potential of RAD402 as a promising therapeutic
candidate for advanced prostate cancer.
Further, Radiopharm is actively engaging with regulatory agencies to finalize the clinical
development pathway, ensuring a streamlined transition into First-In-Human trials in the second
half of 2025. GMP manufacturing is scheduled for completion in H1 2025, incorporating rigorous
quality control measures to support regulatory submissions. The compound's unique mechanism,
leveraging the therapeutic advantages of Tb-161 over traditional isotopes, positions RAD402 as a
differentiated and potentially superior treatment for KLK3-expressing prostate tumors.
Phase I is expected to start in H2 2025.
Strategic Partnerships and Corporate Developments
Lantheus Strategic Investment and Co-Development Agreement
Radiopharm strengthened its collaboration with Lantheus Holdings through an expanded codevelopment agreement for Australia. Under the agreement, Lantheus will fund a Phase 1 imaging
trial targeting multiple solid tumors, with milestone payments of up to USD $2 million to
Radiopharm. Additionally, shortly after the conclusion of the reporting period, Lantheus increased
its equity stake in the Company to 12.16% following an A$8.0 million strategic placement at $A0.06
per share.
BAMF Health Partnership for Brain Metastases Imaging
The Company partnered with BAMF Health to manufacture and dose 18F-RAD101 for its Phase 2b
brain metastases imaging trial. BAMF Health will serve as the initial trial site and leverage its
molecular imaging expertise to enhance study execution.
Nasdaq Listing of American Depositary Shares (ADSs)
On 27 November 2024, Radiopharm successfully listed its ADSs on Nasdaq under the ticker "RADX."
Each ADS represents 300 ordinary shares, with the Nasdaq listing broadening access to U.S.
institutional and retail investors and enhancing visibility within the global radiopharmaceuticals
sector.
Increased Ownership in Radiopharm Ventures
Radiopharm Theranostics increased its stake in Radiopharm Ventures, LLC from 51% to 75%. The
joint venture, formed with MD Anderson Cancer Center in 2022, focuses on radiopharmaceutical
cancer treatments. The decision comes as its lead candidate, a B7H3 monoclonal antibody, nears
preclinical completion, with a Phase 1 trial set for early 2025. Two other preclinical assets have also
shown positive early results. Radiopharm committed an additional US$4 million to fund future
development.
3
Termination of Agreement with Lind Partners
In July 2024, Radiopharm exercised its right to terminate the Share Subscription Agreement and
Share Purchase Agreement with Lind Global Fund II, LP, as part of broader funding arrangements
announced in June 2024. The termination was effective immediately.
Leadership Updates
Appointment of Chief Medical Officer – Dr. Dimitris Voliotis
In August 2024, Radiopharm appointed Dr. Dimitris Voliotis as Chief Medical Officer. Dr. Voliotis
brings extensive expertise in radiopharmaceutical drug development, having held leadership roles
at Bayer, Eisai Inc., and Convergent Therapeutics. His strategic oversight will support the
advancement of Radiopharm’s clinical programs.
Board Appointment – Noel Donnelly
In October 2024, the Company appointed Noel Donnelly as a Non-Executive Director. Mr. Donnelly’s
extensive experience in finance, strategy, and corporate governance, including his role as CFO at
PepGen Inc., strengthens Radiopharm’s leadership team as it continues its global expansion.
For and on behalf of the company,
Riccardo Canevari
CEO and Managing Director
4
Radiopharm Theranostics Limited
Contents
31 December 2024
Directors' report
Auditor's independence declaration
Statement of profit or loss and other comprehensive income
Statement of financial position
Statement of changes in equity
Statement of cash flows
Notes to the financial statements
Directors' declaration
Independent auditor's review report to the members of Radiopharm Theranostics Limited
6
8
9
10
11
12
13
39
40
General information
The financial statements cover Radiopharm Theranostics Limited as a consolidated entity consisting of Radiopharm
Theranostics Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented
in Australian dollars, which is Radiopharm Theranostics Limited's functional and presentation currency.
Radiopharm Theranostics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its
registered office and principal place of business are:
Registered office
Principal place of business
Level 3, 62 Lygon Street, Carlton, Victoria 3053
Level 3, 62 Lygon Street, Carlton, Victoria 3053
A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report,
which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 28 February 2025.
5
Radiopharm Theranostics Limited
Directors' report
31 December 2024
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as
the 'consolidated entity') consisting of Radiopharm Theranostics Limited (referred to hereafter as the 'company' or 'parent
entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2024.
Directors
The following persons held office as directors of Radiopharm Theranostics Limited during the financial period and up
to the date of this report.
Mr Paul Hopper
Mr Riccardo Canevari
Mr Phillip Hains
Mr Ian Turner
Ms Hester Larkin
Dr Leila Alland
Mr Noel Donnelly (appointed 01 October 2024)
Review of Operations & Activities
Information on the financials and operations of the group and its business strategies and prospects is set out in the review of
operations and activities on pages 1 to 4 of this interim financial report.
Significant changes in the state of affairs
On August 5, 2024, Radiopharm announced they had received US$2 million from Lantheus Holdings Inc in accordance with
preclinical asset transfer and development agreement announced on 20 June 2024.
On August 14, 2024, the group completed an Extraordinary General meeting which approved the issue of 1,115 million shares
arising A$46.1 million, issue of 772 million options exercisable at $0.06 and expiring in 2 years from settlement and issue 150
million unlisted options exercisable at $0.05 and expiring in February 2025.
On 26 August 2024, Radiopharm announced they had increased their ownership in Radiopharm Ventures to 75%. To support
further advancement of the trials and to increase the ownership, Radiopharm has committed an additional US$4.0 million to
the joint venture to cover future preclinical and clinical expenses.
On 27 November 2024, Radiopharm announced that American Depository Shares ("ADS") representing its ordinary shares
will commence trading on the Nasdaq Capital Market ("Nasdaq") on 27 November 2024 under the ticker symbol "RADX".
There were no other significant changes in the state of affairs of the consolidated entity during the financial half-year.
Matters subsequent to the end of the financial half-year
On 9 January 2025, the group announced that Lantheus increased its shareholding in Radiopharm to 12.16% with the
placement of 133 million shares raising US$5m (A$8m) at A$0.06 per share. The funds raised will be used for further
development of Radiopharm's clinical pipeline.
No other matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect
the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future
financial years.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this directors' report.
Rounding of amounts
The group is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the 'rounding off' of amounts in the
directors' report and financial report. Amounts in the directors' report and financial report have been rounded off to the nearest
dollar in accordance with the instrument.
6
Radiopharm Theranostics Limited
Directors' report
31 December 2024
This report is made in accordance with a resolution of directors.
On behalf of the directors
___________________________
Mr Paul Hopper
Executive Chairman
28 February 2025
7
Grant Thornton Audit Pty Ltd
Level 22 Tower 5
Collins Square
727 Collins Street
Melbourne VIC 3008
GPO Box 4736
Melbourne VIC 3001
T +61 3 8320 2222
Auditor’s Independence Declaration
To the Directors of Radiopharm Theranostics Limited
In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review
of Radiopharm Theranostics Limited for the half-year ended 31 December 2024. I declare that, to the best of my
knowledge and belief, there have been:
a
no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the
review; and
b
no contraventions of any applicable code of professional conduct in relation to the review.
Grant Thornton Audit Pty Ltd
Chartered Accountants
M A Cunningham
Partner – Audit & Assurance
Melbourne, 28 February 2025
www.grantthornton.com.au
ACN-130 913 594
Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389.
‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or
refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL).
GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member
firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one
another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127
556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards
Legislation.
Radiopharm Theranostics Limited
Statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2024
Note
Revenue
Revenue from contracts with customers
Cost of sales
2
13
Consolidated
31 December 31 December
2024
2023
$
$
1,383,647
(1,614,819)
-
(231,172)
-
1,053,715
235,090
4,065,259
133,929
Expenses
General and administrative expenses
Research and development
Share-based payments expenses
Fair value movement in contingent consideration
(6,342,360)
(13,593,037)
(692,625)
28,060
(6,544,212)
(15,100,020)
(1,487,763)
(5,757,296)
Operating loss
(19,542,329)
(24,690,103)
285
(36,975)
(19,542,044)
(24,727,078)
(100,967)
(31,218)
(19,643,011)
(24,758,296)
Items that may be reclassified subsequently to profit or loss
Foreign currency translation
375,938
8,912
Other comprehensive income for the half-year, net of tax
375,938
8,912
(19,267,073)
(24,749,384)
(917,558)
(18,725,453)
(1,086,457)
(23,671,839)
(19,643,011)
(24,758,296)
(917,558)
(18,349,515)
(1,086,457)
(23,662,927)
(19,267,073)
(24,749,384)
Note
Cents
Cents
19
(1.02)
(7.21)
Gross profit
Other income and expense items
Other gains/(losses)
3
Finance expenses
Loss before income tax expense
Income tax expense
Loss after income tax expense for the half-year
Other comprehensive income
Total comprehensive loss for the half-year
Loss for the half-year is attributable to:
Non-controlling interest
Owners of Radiopharm Theranostics Limited
14
Total comprehensive income for the half-year is attributable to:
Non-controlling interest
Owners of Radiopharm Theranostics Limited
14
Loss per share for loss attributable to the ordinary equity holders of the group:
Basic/diluted loss per share
The above statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
9
Radiopharm Theranostics Limited
Statement of financial position
As at 31 December 2024
Note
Consolidated
31 December
30 June
2024
2024
$
$
Assets
Current assets
Cash and cash equivalents
Trade and other receivables
Assets classified as held for sale
Other current assets
Total current assets
36,436,938
6,250,693
1,665,790
44,353,421
18,575,040
987,413
2,997,592
288,215
22,848,260
57,101
48,001,709
40,000
48,098,810
60,797
49,087,288
40,000
49,188,085
92,452,231
72,036,345
7,334,660
2,242,127
410,201
3,158,664
13,145,652
10,856,793
6,319,189
399,788
17,575,770
27,302,866
27,302,866
27,107,289
27,107,289
Total liabilities
40,448,518
44,683,059
Net assets
52,003,713
27,353,286
4
5
Non-current assets
Property, plant and equipment
Intangible assets
Other financial assets
Total non-current assets
9
Total assets
Liabilities
Current liabilities
Trade and other payables
Other financial liabilities
Employee benefit obligations
Deferred revenue
Total current liabilities
6
7
13
Non-current liabilities
Other financial liabilities
Total non-current liabilities
7
Equity
Share capital
Other equity
Other reserves
Accumulated losses
Equity attributable to the owners of Radiopharm Theranostics Limited
Non-controlling interest
Total equity
10
12
11
168,281,675 100,681,716
849,544
849,544
11,856,085
37,930,072
(127,785,301) (111,338,770)
53,202,003
28,122,562
(1,198,290)
(769,276)
52,003,713
27,353,286
The above statement of financial position should be read in conjunction with the accompanying notes
10
Radiopharm Theranostics Limited
Statement of changes in equity
For the half-year ended 31 December 2024
Attributable to owners of
Radiopharm Theranostics Limited
Consolidated
Share
capital
$
Other
reserves
$
Other
equity
$
Accumulated
losses
$
Noncontrolling
interest
$
Total
equity
$
Balance at 1 July 2023
97,230,329
10,361,457
2,146,566
(65,353,864)
1,194,937
45,579,425
-
-
-
(23,671,839)
(1,086,457)
(24,758,296)
-
8,912
-
-
-
8,912
-
8,912
-
(23,671,839)
(1,086,457)
(24,749,384)
Transactions with owners in
their capacity as owners:
Contributions of equity, net of
transaction costs
Issue of options
Equity-settled payments
1,604,329
223,526
1,852,604
(167,617)
-
-
-
1,604,329
1,852,604
55,909
Balance at 31 December 2023
99,058,184
12,055,356
2,146,566
(89,025,703)
108,480
24,342,883
Loss after income tax expense
for the half-year
Other comprehensive income for
the half-year, net of tax
Total comprehensive income
for the half-year
Attributable to owners of
Radiopharm Theranostics Limited
Consolidated
Balance at 1 July 2024
Loss after income tax expense
for the half-year
Other comprehensive income for
the half-year, net of tax
Total comprehensive income
for the half-year
Transactions with owners in
their capacity as owners:
Contributions of equity, net of
transaction costs) (note 9)
Issue of shares for milestone
completion
Issue of options
Equity-settled payments
Expiration of options
Options forfeited
Cancellation of shares to be
issued
Increase of ownership in RAD
Ventures
Balance at 31 December 2024
Share
capital
$
Other
equity
$
Accumulated
losses
$
Noncontrolling
interest
$
37,930,072 (111,338,770)
(769,276)
27,353,286
Other
reserves
$
Total
equity
$
100,681,716
849,544
-
-
-
(18,725,453)
(917,558)
(19,643,011)
-
-
375,938
-
-
375,938
-
-
375,938
(18,725,453)
(917,558)
(19,267,073)
66,638,719
-
(23,885,229)
-
-
42,753,490
741,400
219,840
-
-
955,055
(231,115)
(2,767,466)
(221,170)
2,767,466
-
-
741,400
955,055
(11,275)
(221,170)
-
-
(300,000)
-
-
(300,000)
-
-
-
(488,544)
488,544
-
168,281,675
849,544
11,856,085 (127,785,301)
(1,198,290)
52,003,713
The above statement of changes in equity should be read in conjunction with the accompanying notes
11
Radiopharm Theranostics Limited
Statement of cash flows
For the half-year ended 31 December 2024
Note
Consolidated
31 December 31 December
2024
2023
$
$
Cash flows from operating activities
Payments to suppliers (inclusive of GST)
Interest received
Research and development tax incentive tax
(22,596,082)
379,616
-
(16,665,626)
40,742
4,851,979
Net cash used in operating activities
(22,216,466)
(11,772,905)
Cash flows from investing activities
Proceeds from disposal of intellectual property
2,997,592
-
Net cash from investing activities
2,997,592
-
Cash flows from financing activities
Proceeds from issue of shares
Share issue transaction costs
Proceeds from borrowings
Repayment of borrowings
Transaction costs related to loans and borrowings
Payments for license fee liabilities and settlement fees
45,842,762
(4,198,440)
(1,900,000)
(218,633)
(2,916,715)
2,113,808
(17,486)
2,967,000
(2,967,000)
(117,000)
-
Net cash from financing activities
36,608,974
1,979,322
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the financial half-year
Effects of exchange rate changes on cash and cash equivalents
17,390,100
18,575,040
471,798
(9,793,583)
11,699,066
(11,558)
Cash and cash equivalents at the end of the financial half-year
36,436,938
1,893,925
7
The above statement of cash flows should be read in conjunction with the accompanying notes
12
Radiopharm Theranostics Limited
Notes to the financial statements
31 December 2024
Note 1. Segments Information
Management has determined, based on the reports reviewed by the chief operating decision maker that are used to make
strategic decisions, that the group has one reportable segment being the research, development and commercialisation of
health technologies. The segment details are therefore fully reflected in the body of the financial report.
Note 2. Revenue from contracts with customers
Consolidated
31 December 31 December
2024
2023
$
$
Revenue from contracts with customers
Revenue recognised over time
1,383,647
-
During the period ended 31 December 2024, the group entered into a strategic development services contract with Lantheus
to advance clinical development of innovative radiopharmaceuticals in Australia. For more information in relation to the group's
policy for recognising revenue refer to note 21.
Note 3. Other gains/(losses)
Consolidated
31 December 31 December
2024
2023
$
$
Net foreign exchange gains
Fair value movement on financing activities (i)
724,877
(489,787)
133,929
-
235,090
133,929
(i) Fair value movement on financing activities
The fair value movement on financing activities relates to the loss made on the termination of the Lind agreement. For more
information, please refer to note 13.
Note 4. Trade and other receivables
Consolidated
31 December
30 June
2024
2024
Current assets
Trade receivables (i)
Accrued receivables (ii)
GST and other receivables
$
$
4,634,056
1,477,021
139,616
802,988
184,425
6,250,693
987,413
(i) Trade receivables
Trade receivables comprise of $4,634,056 relating to the strategic development services contract with Lantheus. For more
information refer to note 13.
(ii) Accrued receivables
Accrued receivables comprise $1,477,021 from the Australian Taxation Office in relation to the R&D tax incentive (30 June
2024: $802,988).
13
Radiopharm Theranostics Limited
Notes to the financial statements
31 December 2024
Note 5. Other current assets
Consolidated
31 December
30 June 2024
2024
$
$
Current assets
Prepayments (i)
Other current assets
1,665,790
-
59,259
228,956
1,665,790
288,215
(i) Prepayments
Prepayments comprise of $50,970 relating to general prepaid expenses and $1,614,820 relating to prepaid expenses for the
strategic development services contract with Lantheus. For more information refer to note 13.
Note 6. Trade and other payables
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
Trade payables
Accrued expenses
Amounts due to employees
R&D Advance
Other payables
14
3,140,032
4,177,993
16,635
6,434,524
1,680,442
490,335
2,003,190
248,302
7,334,660
10,856,793
Radiopharm Theranostics Limited
Notes to the financial statements
31 December 2024
Note 7. Other financial liabilities
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
Diaprost contingent consideration
NanoMab contingent consideration*
NeoIndicate contingent consideration
Pivalate contingent consideration
Pharma15 deferred consideration
TRIMT contingent consideration
MD Anderson Provision
Advanced payment liability
Non-current liabilities
Diaprost contingent consideration
NanoMab contingent consideration*
NeoIndicate contingent consideration
Pivalate contingent consideration
Pharma15 contingent consideration
TRIMT contingent consideration
MD Anderson contingent consideration
1,412,113
226,697
549,925
53,392
-
2,594,015
1,226,994
1,369,290
1,128,890
2,242,127
6,319,189
7,907,879
6,600,353
225,919
1,349,647
1,134,164
8,689,912
1,394,992
9,458,869
5,709,332
439,102
1,775,926
1,347,293
6,915,443
1,461,324
27,302,866
27,107,289
29,544,993
33,426,478
* Payment to be made in the form of ordinary shares in the company, based on the price of the 7 day volume weighted average
price (VWAP) prior to the announcement of the milestone on the ASX.
During the period ended 31 December 2024, the group paid $1,689,721 to terminate the two agreements they had with Lind
Global LP, refer to note 13 for more information. In addition, during the period the group issued US$500k worth of shares and
paid US$500k in cash for the completion of a NanoMab milestone, refer to note 16 for more information.
15
Radiopharm Theranostics Limited
Notes to the financial statements
31 December 2024
Share your feedback
Discover